Sales & Marketing
MiroBio to be acquired by Gilead Sciences
This partnership will accelerate MiroBio’s candidates into treatments for patients
Medicxi, a European life sciences investment firm, has announced that its portfolio company, MiroBio Limited, has entered into a definitive agreement with Gilead Sciences to be acquired for approximately $405 million in cash, subject to customary adjustments.
MiroBio is a privately-held, UK-based biotechnology company, focused on restoring immune balance with agonists targeting immune inhibitory receptors. It was spun out of the University of Oxford in 2019 to develop a new class of medicines known as immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system.
Oxford Science Enterprises and Samsara BioCapital co-led a £27 million Series A investment in 2019. Medicxi invested in the company in June 2022, when it led an £80 million Series B financing.
Nick Williams, Partner at Medicxi, commented: “The acquisition of MiroBio is a testament to the best-in-class discovery engine and highly innovative pipeline they have built. Despite recent advances, significant clinical unmet needs remain in inflammatory and autoimmune diseases with the majority of patients not achieving remission with current therapies.”
Williams was recently appointed as Partner at Medicxi. He oversaw the investment and joined MiroBio’s board.
“By restoring immune homeostasis, MiroBio’s checkpoint agonists have the potential to provide novel and differentiated treatments to these patients,” Williams continued. “We are extremely excited to be partnering with an experienced organisation like Gilead, which will accelerate MiroBio’s candidates into treatments for patients.”
Giovanni Mariggi, co-founder and Partner at Medicxi, commented: “Over a decade of foundational research into inhibitory receptors at Oxford University provided MiroBio with worldleading domain expertise in checkpoint agonism. We are proud to have backed the company as they transition into the clinic and delighted for Nick, our newly-appointed Partner at Medicxi, on his continued success in creating and investing in biotech companies with the aim to deliver meaningful treatments for patients.”